drugset / Trial / NCT06258811
Neoadjuvant Immunochemotherapy for LAOSCC
Phase 3
Recruiting
134 enrolled
Lai-ping Zhong
Central South University · collabFudan University · collabFujian Medical University · collabSun Yat-sen University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the prognostic efficacy of neoadjuvant immunochemotherapy with tislelizumab, albumin paclitaxel and cisplatin followed by radical surgery and adjuvant therapy compared with standard therapy for patients with locally advanced and resectable oral squamous cell carcinoma.
Timeline
- Start
- 2024-02-20
- Primary completion
- 2027-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin paclitaxel | Unknown | 260 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |